Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis.
Markovic-Plese
Silva
S
Jewells
Valerie
V
Speer
Danielle
D
D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000009:adverse effects; D000069059:Atorvastatin; D002490:Central Nervous System / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D064420:Drug-Related Side Effects and Adverse Reactions; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007049:Iatrogenic Disease / Q000517:prevention & control; D007155:Immunologic Factors / Q000008:administration & dosage / Q000009:adverse effects; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011758:Pyrroles / Q000008:administration & dosage / Q000009:adverse effects*; D018570:Risk Assessment
D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D007155:Immunologic Factors; D011758:Pyrroles; D016899:Interferon-beta; D000069059:Atorvastatin